BIOPHARMA CREDIT PLC
Get an alert when BIOPHARMA CREDIT PLC files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£9.4M
USD 12,587,000
+124% vs 2024
Net assets
£862M
USD 1,150,862,000
-2.6% lowest in 3 filed years
Employees
—
Average over period
Profit before tax
£84M
USD 112,334,000
-8.1% vs 2024
Net assets
3-year trend · vs Financials median
Accounts
3-year trend · Δ = latest vs prior filed period · latest reflected 2025-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 | Δ vs prior |
|---|---|---|---|---|---|
| Turnover | — | £111,266,657 | £104,615,960 | -6% | |
| Operating profit | — | £91,533,164 | £97,235,365 | +6.2% | |
| Profit before tax | £81,187,303 | £91,533,164 | £84,094,924 | -8.1% | |
| Net profit | £57,894,894 | £91,464,291 | £84,094,924 | -8.1% | |
| Cash | £101,102,710 | £4,207,217 | £9,422,818 | +124% | |
| Total assets less current liabilities | £1,003,788,741 | £884,663,123 | £861,552,628 | -2.6% | |
| Net assets | £1,003,788,741 | £884,621,949 | £861,552,628 | -2.6% | |
| Equity | £1,003,788,741 | £884,621,949 | £861,552,628 | -2.6% | |
| Average employees | — | — | — | — | |
| Wages | — | — | — | — | |
| Directors' remuneration | £371,313 | £412,487 | £433,448 | +5.1% |
Figures converted to GBP from USD at 0.749 per USD (Frankfurter spot rate) — hover any figure for the original. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Operating margin | — | 82.3% | 92.9% | |
| Net margin | — | 82.2% | 80.4% | |
| Return on capital employed | — | 10.3% | 11.3% | |
| Gearing (liabilities / total assets) | 1.2% | 1.5% | 1.5% | |
| Current ratio | 9.79x | 2.09x | 3.77x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 1 time since incorporation
- BIOPHARMA CREDIT PLC 2017-02-06 → present
- PRECIS (2772) PLC 2016-10-24 → 2017-02-06
Audit & accounting basis
- Accounting basis
- IFRS
- Reporting scope
- Standalone (parent only)
- Auditor
- Ernst & Young, Chartered Accountants
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The Directors consider that it is appropriate to adopt the going concern basis in preparing the financial statements. After making enquiries, and bearing in mind the nature of the Company’s business and its assets, the Directors consider that the Company has adequate resources to continue in operational existence for the foreseeable future, and on this basis, the Company is going concern.”
Group structure
- BIOPHARMA CREDIT PLC · parent
- BPCR Limited Partnership 100%
- Royalty Pharma Loan Bristol-Myers Squibb (BMS) 100%
- LuminDx Holdings, Inc. 100%
- BPCR GP Limited 100%
Significant events
- “On 19 February 2020, the Board approved an interim dividend in respect of the financial period ending 31 December 2025 of $0.03196044 per ordinary share, that was paid on 20 March 2020.”
- “From 11 February 2020 through 18 February 2020, the Company sold 18 million of 1.75 per cent. Cytokinetics, Inc. senior unsecured convertible notes for $200 million and 2.5 per cent. additional consideration of 2.5 per cent. of the loan amount payable upon funding.”
- “On 24 February 2020, the Company and the Private Fund entered into an amended and restated senior term loan agreement with UroGen covering $200 million, plus an additional $75 million for existing term loan and an additional $125 million for new Tranche A.”
- “On 14 March 2020, the Company and the Private Fund entered into an additional senior secured loan agreement with Zenos BioPharma, Inc. The Company will invest up to $100 million plus an additional $125 million, total $225 million.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
6 active · 5 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| MUFG CORPORATE GOVERNANCE LIMITED | Corporate Secretary | 2016-10-24 | — | — |
| HYMAN, Harry Abraham | Director | 2017-02-27 | Aug 1956 | British |
| LEOUZON, Stephanie Marie | Director | 2018-12-05 | Dec 1962 | American |
| REYNOLDS, Nigel Hugh | Director | 2026-01-01 | Apr 1969 | British |
| SHAH, Sapna Hasmukhrai | Director | 2023-03-22 | Apr 1981 | British |
| SODERSTROM, Rolf | Director | 2020-09-16 | Jul 1965 | British |
Show 5 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| CAPITA REGISTRARS LIMITED | Corporate Secretary | 2016-10-24 | 2016-10-24 |
| BOND, Colin Michael | Director | 2016-11-15 | 2026-06-17 |
| BUDGE, Duncan William Allan | Director | 2016-10-24 | 2026-06-17 |
| SILLEM, Jeremy William | Director | 2016-10-24 | 2020-09-16 |
| WILLIS, Hugh John Ramsay | Director | 2016-11-15 | 2017-02-03 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Sardis Capital Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-10-24 | Ceased 2017-03-27 |
Filing timeline
Last 20 of 168 total filings
Material constitutional events — rename, articles re-file, resolution
- 2026-07-02 MA Memorandum articles
- 2026-07-02 RESOLUTIONS Resolution
- 2025-06-16 RESOLUTIONS Resolution
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-07-02 | MA | incorporation | Memorandum articles | |
| 2026-07-02 | RESOLUTIONS | resolution | Resolution | |
| 2026-06-26 | SH03 | capital | Capital return purchase own shares treasury capital date | |
| 2026-06-26 | SH03 | capital | Capital return purchase own shares treasury capital date | |
| 2026-06-25 | TM01 | officers | Termination director company with name termination date | |
| 2026-06-25 | TM01 | officers | Termination director company with name termination date | |
| 2026-06-10 | SH03 | capital | Capital return purchase own shares treasury capital date | |
| 2026-06-10 | SH03 | capital | Capital return purchase own shares treasury capital date | |
| 2026-06-05 | AA | accounts | Accounts with accounts type full | |
| 2026-05-15 | CH01 | officers | Change person director company with change date | |
| 2026-01-09 | AP01 | officers | Appoint person director company with name date | |
| 2025-11-27 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-11-17 | AD03 | address | Move registers to sail company with new address | |
| 2025-11-16 | AD02 | address | Change sail address company with old address new address | |
| 2025-10-24 | SH03 | capital | Capital return purchase own shares treasury capital date | |
| 2025-06-16 | RESOLUTIONS | resolution | Resolution | |
| 2025-06-13 | AA | accounts | Accounts with accounts type full | |
| 2025-06-11 | AD01 | address | Change registered office address company with date old address new address | |
| 2025-06-05 | SH03 | capital | Capital return purchase own shares treasury capital date | |
| 2025-05-27 | SH03 | capital | Capital return purchase own shares treasury capital date |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 15
- Capital events
- 7
- Officers appointed
- 1
- Officers resigned
- 2
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.